Medimmune Limited

Zeneca Limited

Astrazeneca Ab

Astra Zeneca U.k. Limited

Stephen Charles Emery

David Charles Blakey

Qing Zhou

Larry L Green

Bruce Alan Keyt

Xiao-Dong Yang

Clive Graham Copley

Michael Derek Edge

Bruce A Keyt

Paul Elvin

Jeffrey Lester Brown

David C Blakey

Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies directed to angiopoietin-2 and uses thereof

Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Targeted binding agents directed to uPAR and uses thereof

An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Monoclonal antibody to CEA, conjugates comprising said antibody and their therapeutic use

This invention relates particularly to gene directed enzyme prodrug therapy (GDEPT) using post translational glycosylphosphatidylinositol (GPI addition to a prodrug activating enzyme to enable anchorage of the enzyme at the cell surface, particularly for use in cancer therapy. A preferred prodrug activating enzyme is carboxypeptidase G2.

Vector for expression of GPI-enzyme hybrid

The invention provides a gene construct encoding a cell targeting moiety and a heterologous prodrug activating enzyme for use as a medicament in a mammalian host wherein the gene construct is capable of expressing the cell targeting moiety and enzyme as a conjugate within a target cell in the mammalian host and wherein the conjugate is directed to leave the cell thereafter for selective localisation at a cell surface antigen recognised by the cell targeting moiety.

Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety

An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Growing community of inventors

Winterley, United Kingdom

Stephen Charles Emery